<DOC>
	<DOCNO>NCT02295176</DOCNO>
	<brief_summary>Aim study evaluate effect Armolipid Plus insulin sensitivity patient MetS increase LV mass . 168 patient enrol randomized , double-blind , parallel-group , placebo-controlled trial treat 24 week .</brief_summary>
	<brief_title>Metabolic Cardiovascular Effects Armolipid Plus Subjects With Metabolic Syndrome</brief_title>
	<detailed_description>Metabolic syndrome ( MetS ) highly prevalent condition characterize visceral obesity , abnormality glucidic lipid metabolism , increase risk cardiovascular event . Such finding appear associate decrease insulin sensitivity . Management metabolic syndrome currently aim treat individual component disease without address underlie pathophysiologic mechanism ; translate multidrug regimen , high cost patient compliance issue . A complication hypertension hypertrophy leave ventricle ( LV ) , closely related incidence cardiovascular event whose regression result proportional reduction risk . But also factor contribute sex , age , race , genetics , diet insulin resistance . MetS closely related hypertrophy LV . Therefore possible treatment MetS may effective strategy prevention organ damage . Armolipid Plus ( association berberine 500mg , red yeast rice title 3 mg monacolin K , - policosanol 10 mg , coenzyme Q10 2mg , astaxanthin 0,5mg , folic acid 0,2mg ) find effective reduce blood cholesterol triglyceride , improve endothelial function ; subgroup analyse also suggest benefit glucose metabolism , myocardial mass improve diastolic function subject MetS early organ damage . Aim study evaluate effect Armolipid Plus insulin sensitivity patient MetS increase LV mass . 168 patient enrol randomized , double-blind , parallel-group , placebo-controlled trial ; active treatment consist Armolipid Plus ( 1 tbl qd ) . Primary end point reduction insulin resistance patient metabolic syndrome increase LV mass .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<criteria>male Female 1870 age , diagnosis metabolic syndrome , define presence waist circumference &gt; 102 cm ( ♂ ) &gt; 88 cm ( ♀ ) , two criterion : fasting blood glucose &gt; 100 mg systolic blood pressure &gt; 135 diastolic blood pressure &gt; 85 mmHg patient treatment antihypertensive drug triglyceridemia &gt; 150 mg/dl HDL cholesterolemia &lt; 40 mg/dl ( M ) , &lt; 50 mg/dl ( F ) . leave ventricular hypertrophy : leave ventricular mass indexed height &gt; 44 g/m2,7 ( ♀ ) &gt; 48 g/m2 ( ♂ ) . antihypertensive lipidlowering therapy ( applicaple ) stable least three month . ability understand sign inform consent form . pregnancy lactation period diabetes mellitus pharmacological treatment condition hepatic failure creatininemia &gt; 2mg/dl triglyceridemia &gt; 500mg/dl severe obesity ( BMI &gt; 35 ) chronic renal failure glomerular filtration rate &lt; 30ml/min triglyceride &gt; 500mg/dl leave ventricular systolic dysfunction ( LVEF &lt; 40 % ) hypertrophic cardiomyopathy valvular stenosis previous myocardial infarction acinesie intermediate severe cardiac valve disorder intolerance component Armolipid Plus pacemaker generate arrhythmia Inadequately control high blood pressure therapy optimization ( SBP &gt; 140mmHg DBP &gt; 90mmHg ) patient comorbidities allow ( e.g . ischemic heart disease , dysthyroidism ) get stable therapy least 3 month major clinical event last three month ; heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>